BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37162567)

  • 21. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
    Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
    Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
    Singh K; Sathyamurthy A; Ramireddy JK; Ram TS
    J Gastrointest Cancer; 2022 Mar; 53(1):161-169. PubMed ID: 33400211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
    Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
    Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
    Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
    Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
    [No Abstract]   [Full Text] [Related]  

  • 28. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
    Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
    Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
    Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
    Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
    Ludmir EB; Kachnic LA; Czito BG
    Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
    Nilsson MP; Johnsson A; Scherman J
    Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
    Vendrely V; Lemanski C; Pommier P; LE Malicot K; Saint A; Rivin Del Campo E; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; Minsat M; Drouet F; Larrouy A; Peiffert D; Lievre A; Zasadny X; Hautefeuille V; Mornex F; Lepage C; Quero L;
    Radiother Oncol; 2023 Jun; 183():109542. PubMed ID: 36813175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity modulated radiotherapy in anal canal squamous cell carcinoma: Implementation and outcomes.
    Das A; Arunsingh M; Bhattacharyya T; Prasath SS; Balakrishnan A; Mallick I
    J Cancer Res Ther; 2021; 17(4):975-981. PubMed ID: 34528551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
    Rishi A; Rollins M; Ahmed KA; Hunt DC; Sarkar P; Fernandez DC; Hoffman MS; Apte SM; Shahzad MMK; Chon HS; Chern JY; Wenham RM; Montejo ME
    Gynecol Oncol; 2020 Feb; 156(2):349-356. PubMed ID: 31771865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.